← Back to Analyst Consensus 
MIST Buy
Milestone Pharmaceuticals Inc.
Current Price —
Implied Upside —
Analysts 13
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 17, 2026 (22 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 3, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 20, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| May 14, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Jan 6, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Dec 16, 2025 | Wells Fargo | maintain | Overweight → Overweight | $8 | 54% |
| Dec 15, 2025 | TD Cowen | upgrade | Hold → Buy | $8 | 54% |
| Dec 15, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $8 | 44% |
| Sep 11, 2025 | Wells Fargo | initiate | — → Overweight | $4 | 54% |
| Apr 1, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $10 | 44% |
| Mar 28, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Mar 17, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Feb 28, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Jan 27, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Oct 14, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Aug 22, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Aug 22, 2024 | Rodman & Renshaw | initiate | — → Buy | $9 | 40% |
| Jul 1, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| May 30, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| May 16, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Mar 22, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Mar 5, 2024 | Piper Sandler | maintain | Overweight → Overweight | $5 | 54% |
| Feb 26, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Dec 27, 2023 | TD Cowen | maintain | Outperform → Outperform | $9 | 54% |
| Aug 14, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Jun 20, 2023 | Jefferies | downgrade | Buy → Hold | $4 | 52% |
| May 23, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| May 15, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Apr 12, 2023 | Oppenheimer | maintain | — → Outperform | $13 | 52% |
| Mar 30, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $25 | 44% |
| Mar 9, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $25 | 44% |
| Nov 14, 2022 | HC Wainwright & Co. | maintain | — → Buy | $25 | 44% |
| Apr 22, 2022 | Piper Sandler | upgrade | Neutral → Overweight | $10 | 54% |
| Mar 5, 2021 | HC Wainwright & Co. | initiate | — → Buy | $20 | 44% |
| Jul 29, 2020 | Oppenheimer | upgrade | Perform → Outperform | $18 | 52% |
| Jul 24, 2020 | Jefferies | upgrade | Hold → Buy | $15 | 52% |
| Mar 25, 2020 | Jefferies | downgrade | Buy → Hold | $0 | 52% |
| Mar 24, 2020 | Oppenheimer | downgrade | Outperform → Perform | $0 | 52% |
| Mar 24, 2020 | Piper Sandler | downgrade | Overweight → Neutral | $3 | 54% |
| Jun 3, 2019 | Jefferies | initiate | — → Buy | $28 | 52% |
| Jun 3, 2019 | Piper Sandler | initiate | — → Overweight | $26.5 | 54% |
Price Target Trend
Apr 20, 2026 Latest: $5.57 Oct 24, 2026
EPS Estimates
+1q $-0.23
Lo: $-0.27 Hi: $-0.20
5 analysts ▲1
0q $-0.21
Lo: $-0.23 Hi: $-0.20
5 analysts ▲2
+1y $-0.78
Lo: $-0.96 Hi: $-0.59
5 analysts ▲2
0y $-0.84
Lo: $-0.90 Hi: $-0.77
5 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days